Next Generation of CO2 Incubators for Demanding Cell Culture Applications
Cell culture scientists working with sensitive cultures such as stem and primary cells, can turn to a new CO2 incubator that combines the latest technologies for optimal cell growth and contamination control designed to create uniform growth conditions with consistency and reliability.
The Thermo Scientific Heracell VIOS incubator series is ideal for academic research and pharmaceutical applications, allowing scientists to maximize their productivity with excellent reproducibility, reliability and efficiency.
“Reproducibility and contamination prevention are critical when it comes to sensitive cultures to ensure the integrity of your research,” said Doug Wernerspach, Global Business Director, Thermo Fisher Scientific. “Our new Heracell VIOS series leverage our long history of CO2 technology leadership with innovations, including our new THRIVE active airflow and proven decontamination that are critical for today’s demanding cell culture applications.”
Incorporating the breakthrough THRIVE active airflow technology, the Heracell VIOS delivers a homogeneous culturing environment with fast recovery for unwanted variation. Designed to protect valuable cultures from contamination, the Heracell VIOS is equipped with
• ISO class 5 HEPA filters to protect against airborne microbes and particulates
• Steri-Run, a fully automatic on-demand overnight 180 °C sterilisation cycle assures uniform 6-log high-temperature sterilisation on all surfaces
• Condensation-free chamber with covered, protected humidity reservoir
• 100% pure copper interiors to provide lasting sustainability and easy maintenance.
For operation simplicity, the intelligent iCAN touchscreen interface provides complete data visibility to monitor all incubator interaction, featuring on-screen menu prompts, error and usage monitoring, downloadable data logging with a standard USB, performance trend graphing and multiple language selection, including English, Spanish, German, French, Italian, Japanese and Mandarin.
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance